Evidence map›Paper›PMID 40259826›Full record

ArticleThe Journal of international medical research2025

Description of schizophrenia treatment outcomes in Saudi Arabia: A preliminary pilot investigation.

Fatimah AlDosari, Shahad AlGhossen, Malka Alburaiki, Sireen Ar Shilbayeh, Nada AlBogami, Ammena Y Binsaleh, Nadia Al Mazrouei, Hayam A AlRasheed, Khlood M Aldossary, Omar Gammoh

Abstract read
In one paragraph

Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fatimah AlDosariPharmaceutical Care Department, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Shahad AlGhossenPharmaceutical Care Department, King Abdulaziz Medical City-Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Malka AlburaikiPsychiatry Department, Security Forces Hospital (SFH), Riyadh, Saudi Arabia.
Sireen Ar ShilbayehDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID 0000-0002-5020-6838
Nada AlBogamiPsychiatry Department, Security Forces Hospital (SFH), Riyadh, Saudi Arabia.
Ammena Y BinsalehDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Nadia Al MazroueiPharmacy Practice and Pharmacotherapeutics Department, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
Hayam A AlRasheedDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID 0009-0002-6186-848X
Khlood M AldossaryDepartment of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.ORCID 0000-0002-8649-3365
Omar GammohDepartment of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.ORCID 0000-0001-8801-2652

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectivesSchizophrenia is a debilitating psychiatric illness that is often understudied due to stigma and cultural barriers. This report presents a clinical descriptive evaluation of patients with schizophrenia in Saudi Arabia, focusing on demographics, clinical information, and treatment efficacy and safety.MethodsThis single-center cross-sectional study included 42 patients on antipsychotics for at least 6 months, with a male-to-female ratio of 1:1 and a mean age of 36 years.ResultsMost patients were single (64.3%) and unemployed (51.2%), with 52.4% having only a high school education level. The median duration of antipsychotic treatment was 21.2  (1.7-227.5) months. Antipsychotic combination therapy was the most common intervention (59.5%). Efficacy results from the Positive and Negative Syndrome Scale showed complete remission in 4.8%, partial remission in 11.9%, moderate remission in 33.3%, and no improvement in 50% of the patients. Safety evaluation via the modified Simpson-Angus Scale indicated that 71.4% of the patients had normal scores, 26.2% experienced minimal movement disorders, and only 2.4% had clinically significant movement symptoms.ConclusionThis preliminary investigation examined the demographics and clinical features of patients with schizophrenia as well as efficacy and tolerability of relevant treatments. Larger studies are needed to understand this population comprehensively.

Indexed as

Antipsychotic AgentsSchizophreniaAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedPilot ProjectsSaudi ArabiaTreatment OutcomeYoung AdultAntipsychotic Agentsantipsychotic drugseffectivenesssafetySaudi ArabiaSchizophreniatherapy

Identifiers

PMID40259826
PMCPMC12035046

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.